Our strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products.

We believe that exploring opportunities to expand the market potential for our existing commercial stage products represents our lowest risk growth strategy.  The Company is continually evaluating new opportunities to further the clinical development of our products, whether by exploring new potential indications to expand labeling and help new patient populations or by developing new clinical data to further support our existing markets and the efforts of our commercial organization.

The Company focuses on the hospital acute care, gastroenterology and oncology market segments that both feature concentrated prescriber bases. Our sales and marketing efforts are focused on expanding our reach within the medical community and keeping healthcare providers informed of how our products are able to improve the quality of care for their patients. The combination of our ongoing development activities and marketing efforts drives the success of our products.